These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 34725737)

  • 1. How does nintedanib overcome cancer drug-resistant mutation of RET protein-tyrosine kinase: insights from molecular dynamics simulations.
    Cao S; Jiang X; Tan C; Fu M; Xiong W; Ji D; Lv J
    J Mol Model; 2021 Nov; 27(11):337. PubMed ID: 34725737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.
    Terzyan SS; Shen T; Liu X; Huang Q; Teng P; Zhou M; Hilberg F; Cai J; Mooers BHM; Wu J
    J Biol Chem; 2019 Jul; 294(27):10428-10437. PubMed ID: 31118272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multikinase inhibitors in thyroid cancer.
    Licitra L; Locati LD
    Ann Oncol; 2012 Sep; 23 Suppl 10():x328-33. PubMed ID: 22987985
    [No Abstract]   [Full Text] [Related]  

  • 4. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.
    Cuccuru G; Lanzi C; Cassinelli G; Pratesi G; Tortoreto M; Petrangolini G; Seregni E; Martinetti A; Laccabue D; Zanchi C; Zunino F
    J Natl Cancer Inst; 2004 Jul; 96(13):1006-14. PubMed ID: 15240784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into pralsetinib resistance to the non-gatekeeper RET kinase G810C mutation through molecular dynamics simulations.
    Cao S; Tan C; Fei A; Hu G; Fu M; Lv J
    J Mol Model; 2022 Dec; 29(1):24. PubMed ID: 36576611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of wild-type and mutated RET proto- oncogene associated with familial medullary thyroid cancer.
    Masbi MH; Mohammadiasl J; Galehdari H; Ahmadzadeh A; Tabatabaiefar MA; Golchin N; Haghpanah V; Rahim F
    Asian Pac J Cancer Prev; 2014; 15(5):2027-33. PubMed ID: 24716929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.
    de Groot JW; Plaza Menacho I; Schepers H; Drenth-Diephuis LJ; Osinga J; Plukker JT; Links TP; Eggen BJ; Hofstra RM
    Surgery; 2006 Jun; 139(6):806-14. PubMed ID: 16782438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.
    Gorla L; Mondellini P; Cuccuru G; Miccichè F; Cassinelli G; Cremona M; Pierotti MA; Lanzi C; Bongarzone I
    Mol Carcinog; 2009 Mar; 48(3):220-231. PubMed ID: 18756447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Familial medullary thyroid carcinoma: case report and literature review.].
    Barletta Carrillo CF; Poterico Rojas JA; Barrionuevo Cornejo C; Casavilca Zambrano S; Pinedo Cárdenas A; Quispe Santibañez I; Castro Mujica MDC
    Rev Fac Cien Med Univ Nac Cordoba; 2018 Dec; 75(4):303-309. PubMed ID: 30734711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
    Meng S; Wu H; Wang J; Qiu Q
    Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey.
    Aydoğan Bİ; Yüksel B; Tuna MM; Navdar Başaran M; Akkurt Kocaeli A; Ertörer ME; Aydın K; Güldiken S; Şimşek Y; Cihan Karaca Z; Yılmaz M; Aktürk M; Anaforoğlu İ; Kebapçı N; Duran C; Taşlıpınar A; Kulaksızoğlu M; Gürsoy A; Dağdelen S; Erdoğan MF
    J Clin Res Pediatr Endocrinol; 2016 Mar; 8(1):13-20. PubMed ID: 26758973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotypic characteristics and their association with phenotypic characteristics of hereditary medullary thyroid carcinoma in Korea.
    Jung KY; Kim SM; Kim MJ; Cho SW; Kim BW; Lee YS; Jeong JJ; Nam KH; Chung WY; Lee KE; Chung EJ; Kim HJ; Park DJ; Sung MW; Park CS; Cho BY; Park YJ; Chang HS
    Surgery; 2018 Aug; 164(2):312-318. PubMed ID: 29779869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
    Krampitz GW; Norton JA
    Cancer; 2014 Jul; 120(13):1920-31. PubMed ID: 24699901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P
    Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A Case of Hereditary Medullary Thyroid Cancer (MEN2A/FMTC) Diagnosed at the Time of Recurrence].
    Enomoto K; Shimizu K; Hirose M; Miyabe H; Morizane N; Takenaka Y; Shimazu K; Fushimi H; Uno A
    Nihon Jibiinkoka Gakkai Kaiho; 2015 Mar; 118(3):219-23. PubMed ID: 26349338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early, Prophylactic Thyroidectomy in Hereditary Medullary Thyroid Carcinoma: A 26-year Monoinstitutional Experience.
    Pelizzo MR; Torresan F; Boschin IM; Nacamulli D; Pennelli G; Barollo S; Rubello D; Mian C
    Am J Clin Oncol; 2015 Oct; 38(5):508-13. PubMed ID: 24064755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression.
    Smith J; Read ML; Hoffman J; Brown R; Bradshaw B; Campbell C; Cole T; Navas JD; Eatock F; Gundara JS; Lian E; Mcmullan D; Morgan NV; Mulligan L; Morrison PJ; Robledo M; Simpson MA; Smith VE; Stewart S; Trembath RC; Sidhu S; Togneri FS; Wake NC; Wallis Y; Watkinson JC; Maher ER; McCabe CJ; Woodward ER
    Hum Mol Genet; 2016 May; 25(9):1836-45. PubMed ID: 26945007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple endocrine neoplasia type 2A in two families with the familial medullary thyroid carcinoma associated G533C mutation of the RET proto-oncogene.
    Peppa M; Boutati E; Kamakari S; Pikounis V; Peros G; Panayiotides IG; Economopoulos T; Raptis SA; Hadjidakis D
    Eur J Endocrinol; 2008 Dec; 159(6):767-71. PubMed ID: 18805915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.
    Strock CJ; Park JI; Rosen M; Dionne C; Ruggeri B; Jones-Bolin S; Denmeade SR; Ball DW; Nelkin BD
    Cancer Res; 2003 Sep; 63(17):5559-63. PubMed ID: 14500395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.
    Petrangolini G; Cuccuru G; Lanzi C; Tortoreto M; Belluco S; Pratesi G; Cassinelli G; Zunino F
    Biochem Pharmacol; 2006 Aug; 72(4):405-14. PubMed ID: 16756963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.